Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Mar 10;322(7286):577-9.
doi: 10.1136/bmj.322.7286.577.

Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial

P Diggory  1 , C Fernandez, A Humphrey, V Jones, M Murphy
Affiliations
Clinical Trial

Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial

P Diggory et al. BMJ. .

Abstract

Objective: To determine whether elderly people can learn to use the inhaler used to deliver zanamivir (Relenza Diskhaler) as effectively as the Turbohaler and to identify which aspects of inhaler technique are most problematic.

Design: Randomised, controlled, intervention study.

Setting: Wards for acute elderly care in a large district general hospital.

Participants: 73 patients who were unfamiliar with the use of an inhaler, aged 71 to 99 (mean 83) years.

Main outcome measures: Initial scores and changes in scores 24 hours later using a 10 point scoring system of five aspects of inhaler technique.

Results: 38 patients were allocated the Relenza Diskhaler and 35 the Turbohaler. The mean total score was significantly greater in the Turbohaler than Diskhaler groups both initially (8.74 v 7.05) and after 24 hours (8.28 v 5.43). The major difference between inhalers was in loading and priming. After tuition 50% (19 of 38) of patients allocated the Diskhaler were unable to load and prime the device and 65% (24 of 37) were unable to do so 24 hours later. Of those allocated the Turbohaler, two patients were unable to load and prime the device after initial review and one after 24 hours.

Conclusion: Most elderly people cannot use the inhaler device used to deliver the anti-influenza drug zanamivir. Treatment with this drug is unlikely to be effective in elderly people unless the delivery system is improved.

PubMed Disclaimer

Figures

Figure
Figure
Trial profile
See this image and copyright information in PMC

Comment in

References

    1. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med. 1998;32:20–25. - PubMed
    1. Department of Health. Immunisation against infectious diseases. London: DoH; 1996. pp. 120–133.
    1. Anon. Influenza vaccination and older people. Effectiveness Matters. 1996;2:1–4.
    1. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New Engl J Med. 1997;337:874–880. - PubMed
    1. MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877–1881. - PubMed